ArticleMedicine2025
Loffler endocarditis as an initial manifestation of lung adenocarcinoma: A case report.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
rationaleLöffler endocarditis, a rare form of hypereosinophilic syndrome (HES), is characterized by transient left ventricular endomyocardial thickening, intracardiac thrombi, and eosinophilic infiltration. Its occurrence as a paraneoplastic manifestation of solid tumors, particularly lung adenocarcinoma, is exceedingly rare and underrecognized. PATIENT CONCERNS: A 75-year-old male smoker presented with progressive dyspnea (New York Heart Association Class III) and bilateral leg edema. DIAGNOSES: He had no history of asthma, allergy, or parasitic infection. Physical examination revealed jugular venous distention and bilateral crackles. Laboratory tests showed marked hypereosinophilia (15.29 × 109/L). Transthoracic echocardiography demonstrated endomyocardial thickening, reduced left ventricular compliance, and mobile intracardiac thrombi. Computed tomography angiography revealed a spiculated left upper lobe lung mass with mediastinal lymphadenopathy.
interventionsSymptoms developed over 4 weeks. Hypereosinophilia and cardiac abnormalities were identified at presentation. The lung mass was detected on initial imaging; histopathology confirmed adenocarcinoma (biopsy-proven). Despite anticoagulation and heart failure therapy, the patient declined corticosteroids and oncologic treatment. Clinical deterioration occurred within 2 weeks, leading to death. The patient received guideline-directed medical therapy for heart failure (beta-blocker, angiotensin-converting enzyme inhibitor, diuretics), anticoagulation (low-molecular-weight heparin), and diagnostic bronchoscopic biopsy. Corticosteroids and chemotherapy were recommended but refused by the family. OUTCOMES: The patient's condition rapidly worsened due to progressive heart failure and untreated malignancy. LESSONS: This case highlights the importance of considering occult malignancy in unexplained HES with cardiac involvement. It is the first reported case of Löffler endocarditis as a paraneoplastic manifestation of lung adenocarcinoma. Limitations include the lack of postmortem examination and the inability to initiate immunosuppressive or antitumor therapy due to patient refusal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.